Working… Menu

A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) (LAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03062943
Recruitment Status : Recruiting
First Posted : February 24, 2017
Last Update Posted : August 8, 2019
Information provided by (Responsible Party):
IRCCS Multimedica

Brief Summary:
This trial is conducted locally. The aim of this trial is assess the efficacy and a favorable benefit-risk ratio for nintedanib in the treatment of LAM at the dose of 150 mg bid

Condition or disease Intervention/treatment Phase
Lymphangioleiomyomatosis Drug: Nintedanib Phase 2

Detailed Description:

There is a high unmet medical need for efficacious and safe treatment of LAM, to halt lung function decline, improve patient-reported outcome, reduce size of angiomyolipomas and ultimately decrease mortality. Guidelines recommend participation in research trials if possible.

To date, therapeutic options include mTOR inhibitors sirolimus and everolimus. Among these, sirolimus, has been approved by FDA based on a clinical trial which showed a stabilization of lung function expressed as FEV1 during the 12 month treatment period. Thus the stabilization of lung function appears to require continuous exposure to the drug. Sirolimus is associated with an increased frequency of adverse events like mucositis, gastrointestinal events, hypercholesterolemia, acneiform rash, and swelling in the lower extremities.

Nintedanib was shown to dose-dependently inhibit PDGFR phosphorylation and subsequent signaling via protein kinase B (Akt) and extracellular signal-regulated kinase (ERK) 1/2 in lung tissue from mice. Akt and ERK 2 can both phosphorylate tuberin resulting in inactivation of hamartin-tuberin complex and consequent activation of mTOR .

It has been demonstrated that platelet-derived growth factor β receptor (PDGFRβ) is present and active in human and murine TSC lesions. Thus, an inhibition of PDGFR may be effective in LAM. Moreover, the inhibition of VEGF, PDGF and FGF signaling pathways reduces tumor angiogenesis in lung. As angiogenesis and lymphangiogenesis are mechanisms involved in dissemination of LAM cells, potential inhibition of angiogenesis by nintedanib may contribute to prevent disease progression in LAM.

Therefore, a non-randomized, efficacy, safety, and tolerability trial of nintedanib in sporadic and TSC-associated LAM is proposed.

The objective of the trial is to assess the efficacy and a favorable benefit-risk ratio for nintedanib in the treatment of LAM at the dose of 150 mg bid.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
Study Start Date : October 2016
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : October 2020

Arm Intervention/treatment
Experimental: Nintedanib 150mg BID
nintedanib soft gelatine capsules Dose: 150 mg bid Mode of admin. : Oral Duration of treatment: 1 year Duration of follow-up: 12 months after treatment discontinuation
Drug: Nintedanib
Other Name: OFEV

Primary Outcome Measures :
  1. FEV1 rate decline [ Time Frame: up to 12 months ]
    Change in FEV1 (Force Expiratory Volume in 1 second) in milliliters per month. The FEV1 slope will be calculated at baseline and at 3, 6, 9 and up to 12 months during the treatment phase.

Secondary Outcome Measures :
  1. Safety and Tolerability in terms of AEs, particularly for liver function and level of hepatic enzymes. [ Time Frame: up to 12 months ]
    Safety and Tolerability profile: assessment of any AEs, increased levels of hepatic enzymes, kidney and gastrointestinal tract functionality. All the adverse events will be classified depending of time of occurency: treatment emergent adverse events if they occur after the first dose of study medication up to a period of 28 days or alternatively as either to the screening or post treatment, or post study phase, as appropriate.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written Informed Consent for participating to trial.
  • Patient aged ≥ 18 years at visit 1.
  • Sporadic or TSC associated LAM, classified as ''definite'' by the European Respiratory Society criteria and /or serum VEGFD level >/= 800 mg/ml, and evidence of a 10% deterioration in FEV1 and /or loss of 80 ml of FEV1 or more in the last year (post bronchodilator). Also LAM patients with proven side effects and/or toxicities/ contraindications to sirolimus therapy will be eligible for this study.

Exclusion Criteria:

Laboratory parameters have to satisfy entry criteria as shown below:

  • Laboratory parameters (screening)

    • AST, ALT > 1.5 x ULN
    • Bilirubin > 1.5 x ULN
  • Positivity for HIV or Hepatitis.
  • Chylous effusions.
  • Relapsing pneumothorax.
  • Angiomyolipoma > 5 cm.
  • Treatment with mTOR inhibitors in the last month.
  • Patient eligible for Lung Transplantation.
  • Hormone therapy.
  • Patients are excluded if they are post lung transplant or had previously been diagnosed with a pneumothorax, chylous effusion, bleeding angiomyolipoma within the previous 6 months.
  • Current smokers.
  • Other diseases:

    • Cardiac disease.
    • Myocardial infarction within 6 months of visit 2.
    • Unstable angina within 1 month of visit 2.
  • Bleeding Risk:

    • Known genetic predisposition to bleeding.
  • Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, heparin, NOA) or high dose antiplatelet therapy2.
  • History of haemorrhagic central nervous system (CNS) event within 12 months prior to visit 1.
  • History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers and/or major injury or surgery within 3 months prior to visit 1.
  • International normalised ratio (INR) > 2 at visit 1.
  • Prothrombin time (PT) and partial thromboplastin time (PTT) > 150% of institutional ULN at visit 1.
  • Planned major surgery during the trial participation, including lung transplantation, major abdominal or major intestinal surgery.
  • History of thrombotic event (including stroke and transient ischemic attack) within 12 months of visit 1.
  • History of end-stage renal disease requiring dialysis.
  • Alcohol or drug abuse which in the opinion of the treating physician would interfere with treatment.
  • Pts that cannot perform PFT and cannot give informed consent.
  • Known hypersensitivity to the trial drug or its components.
  • Other disease that may interfere with testing procedures or in the judgement of the Investigator may interfere with trial participation or may put the patient at risk when participating in this trial.

General Exclusion Criteria:

  • Previous treatment with nintedanib.
  • Other investigational therapy (participation in research trial) received within 8 weeks of visit.
  • Thoracic, abdominal, gynecological, neurologic surgical procedures planned to occur during trial period.
  • Pregnant women or women who are breast feeding or of child bearing potential not using two effective methods of birth control (one barrier and one highly effective non-barrier) for at least 1 month prior to enrolment (and until 3 months after treatment end).
  • Female patients will be considered to be of childbearing potential unless surgically sterilised by hysterectomy or bilateral tubal ligation, or postmenopausal for at least two years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03062943

Layout table for location contacts
Contact: Sergio A Harari, MD +39 02 85 99 4580
Contact: Mara Cattaneo +39 02 85 99 4127

Layout table for location information
Pneumology unit Recruiting
Milan, Italy, 20123
Contact: Sergio A Harari, MD    +39 02 55 40 4580   
Contact: Mara Cattaeno    +39 02 55 40 4127   
Principal Investigator: Sergio A Harari, MD         
Sub-Investigator: Olga Torre, MD         
Sub-Investigator: Roberto Cassandro, MD         
Sponsors and Collaborators
IRCCS Multimedica
Layout table for investigator information
Principal Investigator: Sergio A Harari, MD MultiMedica - San Giuseppe Hospital
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: IRCCS Multimedica Identifier: NCT03062943    
Other Study ID Numbers: IISS LAM
First Posted: February 24, 2017    Key Record Dates
Last Update Posted: August 8, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphatic Vessel Tumors
Neoplasms by Histologic Type
Perivascular Epithelioid Cell Neoplasms
Neoplasms, Connective and Soft Tissue
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action